Navigation Links
Osteotech's Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
Date:7/29/2008

dquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, this press release or the conference call, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of July 29, 2008 and the Company does not intend to update this information.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Osteotechs Plexur(R) Technology to Be Used in Craniofacial Reconstruction Program Funded by the Armed Forces Institute of Regenerative Medicine
2. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
3. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
4. Simbionix Releases Powerful New Learning Management System With Enhanced True Assessment System(TM)
5. Studies Show USGI Medicals EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass
6. EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board
7. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
8. EnzySurge, Maker of DermaStream(TM), Completes Funding Round of US$4 Million
9. More Than 700 Physicians and Administrators Participate in the Visian ICL Growth Program(TM) Launch
10. Elusys Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
11. EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...lif. Nov. 5, 2009 Complete Genomics, a third-gen...ounced publication of a report in the journal Sci...atform, including analysis of sequence data from t...for these three genomes sequenced on the proof-of-...5 for 87x coverage to $1,726 for 45x coverage for ...
(Date:11/6/2009)... 6 BioSpecifics Technolo...ompany developing first-in-class collagenase-based...or the third quarter ended September 30, 2009. ,... this year, the FDA,s Arthritis Advisory Committee...pproval of XIAFLEX(TM) for the treatment of Dupuyt...
(Date:11/6/2009)... November 6 EUCODIS Bioscience, a ...d marketing enzymes for the,chemical industry anno...reement with Bio Sidus, the leading biopharmaceuti...ment gives EUCODIS Bioscience exclusive access - f...s, proprietary collection of,psychrophilic bacteri...
(Date:11/6/2009)...ewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:...today announced updated results from a Phase II st...rcomas metastatic to the lung in a poster presenta... Society Meeting held in Miami Beach, Florida, fro...titled "A Phase II Study of Intravenous REOLYSIN (...
Breaking Biology Technology:Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3
...rmaceuticals,Inc. (Nasdaq: CADX ), a biopharmaceu...nd commercializing proprietary product candidates ...nced today that the company,s,President and CEO Th...ew on,Monday, June 23, 2008 at 1:05pm Eastern Time...ain Roundtable Conference at the Sofitel Hotel in ...
...nies, The Integra Group of Brooklyn Park and, Na...speed the path to market for advances ...and SAN DIEGO, June 17 Coinciding,with the BIO In...terventions introduces the "Mouse Stent Model" for...s. The model, complete with a mini-stent of,specta...
...,s focus in key areas in contract research, includ...l monitoring, and data management/e...7 PROMETRIKA, LLC, a contract,research organizati...vices,for clients in pharmaceuticals, biologics an...es Kolb has joined the company as senior director,...
Other Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York 2NanoInterventions Launches New, Rapid Testing System for Coronary Stents 2NanoInterventions Launches New, Rapid Testing System for Coronary Stents 3Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management 2Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management 3
(Date:11/9/2009)... children with cancer, the hopeful news is that pe...decades. Among the bad newstreatments that enable ...osed with cancer who have reached puberty currentl... before undergoing cancer treatment, they may have...Younger boys, however, do not produce sperm, altho...
(Date:11/9/2009)...Ala. The U.S. Department of Energy (DOE) has anno...Alabama at Birmingham (UAB) School of Engineering ...gas emissions through the capture and permanent sa...O2). The project is in collaboration with Southern... Funded by the DOE through the 2009 American Recov...
(Date:11/9/2009)...ournal Naturwissenschaften is publishing a speci...dern Biology" to commemorate Darwin,s On the Origi...November 1859. Guest editor and author of the lead...nt physiology and evolutionary biology at the Univ...special issue are available free of charge until 3...
Breaking Biology News(10 mins):For young boys with cancer, testicular tissue banking may be option to preserve fertility 2For young boys with cancer, testicular tissue banking may be option to preserve fertility 3UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 1Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 2Allied Worlds Susan Chmieleski to Speak at American Society for Healthcare Risk Management 28ASHRM 29 Annual Conference and Exhibition 59740 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 1New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 2New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 3New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 4New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 5New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 6New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 7New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 8New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 9New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 10New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 11New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 12New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 13New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 14New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 15New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 16New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 17New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 18New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 19New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 20New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 21New SIMPONI 28TM 29 Data Show Long Term Efficacy in Treatment of Rheumatoid Arthritis 14525 22Ikaria 28R 29 Names New Chairman 14523 1Ikaria 28R 29 Names New Chairman 14523 2
...ts including researchers at Cold Spring Harbor Lab...irst biomarker that permits neural stem and progen...n the brains of living human subjects. This import...gnosis and monitoring of brain tumors and a range ... , The biomarker is a lipid molecule whose presen...
...e National Institute of Standards of Technology (N... what is probably the worlds smallest microwave ov... drop of liquid inside a container slightly shorte...he micro microwave is intended for lab-on-a-chip d...es on tiny samples. , In a paper in the November ...
...ajor component of green tea could prove the perfec...tem response to a bacterial infection. In a new la...n Institute for Medical Research, and his colleagu...zens of Chinese herbal compounds in reversing a fa...very year. They found that an ingredient in green ...
Other Biology News:Team of scientists develops non-invasive method to track nerve-cell development in live human brain 2Micro microwave does pinpoint cooking for miniaturized labs 2In the laboratory, green tea proves a powerful medicine against severe sepsis 2
CoverWell imaging chamber gasket with adhesive, one chamber, 20 mm diameter, 1.0 mm deep *set of 40* from Molecular Probes (Invitrogen)
Canine IL-10 ELISpot Development Kit from R&D Systems
Equine TNF ALPHA from AbD Serotec
DETACHaBEAD CD19 from Dynal Biotech
Biology Products: